Health and Fitness Health and Fitness
Mon, June 4, 2012
Sat, June 2, 2012
Fri, June 1, 2012
Thu, May 31, 2012
Wed, May 30, 2012
Tue, May 29, 2012
Mon, May 28, 2012
Sun, May 27, 2012
Sat, May 26, 2012
Fri, May 25, 2012
[ Fri, May 25th 2012 ] - Market Wire
GenVec Reports Inducement Award
Thu, May 24, 2012
Wed, May 23, 2012
[ Wed, May 23rd 2012 ] - Market Wire
Moody's Upgrades Mylan
Tue, May 22, 2012

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences


//health-fitness.news-articles.net/content/2012/ .. to-present-at-upcoming-investor-conferences.html
Published in Health and Fitness on Tuesday, May 29th 2012 at 13:20 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ ])--[ Ironwood Pharmaceuticals, Inc. ] (NASDAQ: IRWD) will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5, 2012 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) at Terranea Resort in Rancho Palos Verdes, CA.

In addition, Ironwood management will also present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 4:00 p.m. Eastern Time at the Grand Hyatt New York.

A live webcast of Ironwoodas presentations will be accessible through the Investors section of the companyas website at [ www.ironwoodpharma.com ]. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwoodas website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwoodas guanylate cyclase-C agonist (GCCA), is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotideas development program has been completed and supports the submitted NDA submission for both indications, as well as the MAA submission in Europe for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit [ www.ironwoodpharma.com ].


Publication Contributing Sources